Nurix Therapeutics, Inc. (NRIX)
25.57
-0.47
(-1.80%)
USD |
NASDAQ |
Sep 02, 14:16
Nurix Therapeutics Research and Development Expense (Annual) : 308.16M for Nov. 30, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| November 30, 2025 | 308.16M |
| November 30, 2024 | 212.31M |
| November 30, 2023 | 181.62M |
| November 30, 2022 | 179.15M |
| Date | Value |
|---|---|
| November 30, 2021 | 113.64M |
| November 30, 2020 | 64.31M |
| November 30, 2019 | 42.67M |
| November 30, 2018 | 37.53M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Monte Rosa Therapeutics, Inc. | 133.14M |
| Gilead Sciences, Inc. | 5.688B |
| TG Therapeutics, Inc. | 160.22M |
| Cue Biopharma, Inc. | 37.43M |
| Keros Therapeutics, Inc. | 127.09M |